AN2 Therapeutics (ANTX) vs NervGen Pharma (NGEN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
AN2 Therapeutics (ANTX) has outperformed NervGen Pharma (NGEN) over the past year, gaining 262.8% versus a loss of 44.1%. NervGen Pharma is the larger company by market cap ($188.2 million vs $176.6 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ANTX | NGEN |
|---|---|---|
| Share price | $4.68 | $1.75 |
| Market cap | $176.61M | $188.16M |
| 1-day change | -3.51% | +0.57% |
| YTD return | +310.53% | -68.93% |
| 1-year return | +262.79% | -44.12% |
| 5-year return | — | -7.94% |
| EPS (TTM) | $-1.05 | $-0.58 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $7.19 | $6.30 |
| 52-week low | $1.00 | $1.58 |
| Distance from 52-week high | -34.91% | -72.22% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +92.31% | +471.43% |
| Average volume | 240.21K | 565.19K |
| Shares outstanding | 37.74M | 107.52M |
| Employees | 21 | 9 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ANTX has outperformed NGEN by 306.9 percentage points over the past year.
About AN2 Therapeutics
ANTX stock →AN2 Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics. The company's initial candidate includes epetraborole, which is phase 3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease, as well as studying for the treatment of acute melioidosis.
Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees
About NervGen Pharma
NGEN stock →NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer's disease; and NVG-300, which is in a preclinical model of ischemic stroke, amyotrophic lateral sclerosis, and confirmatory SCI study.
Health Care · Biotechnology: Pharmaceutical Preparations · 9 employees
ANTX vs NGEN FAQ
Which is bigger, AN2 Therapeutics or NervGen Pharma?
NervGen Pharma (NGEN) is larger, with a market capitalization of $188.16M compared with $176.61M for AN2 Therapeutics (ANTX).
Which stock has performed better over the past year, ANTX or NGEN?
ANTX returned +262.79% over the past 12 months, compared with -44.12% for NGEN (price return, excluding dividends). Past performance does not predict future results.
Are AN2 Therapeutics and NervGen Pharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.